Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 17Neoplasm Metastasis 6Carcinoma, Non-Small-Cell Lung 3Brain Neoplasms 3Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Colorectal Neoplasms 2Solid Cancer 1Salivary Gland Neoplasms 1Recurrence 1Pancreatic Neoplasms 1Neoplasm, Residual 1HER2-positive Breast Cancer 1HER2-mutant Non-Small Cell Lung Cancer 1HER2-Positive Primary Breast Cancer 1Gastric Adenocarcinoma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colonic Neoplasms 1Carcinosarcoma 1Breast Diseases 1Adenocarcinoma Of Esophagus 1Adenocarcinoma 1

Interventions

Specimen Handling 6Magnetic Resonance Spectroscopy 5Biopsy 4pembrolizumab 2olaparib 2durvalumab 2ceralasertib 2Nivolumab 2trastuzumab deruxtecan 1pelcitoclax 1pazopanib 1cobimetinib 1cediranib 1capivasertib 1cabozantinib 1X-Rays 1Taxes 1Radiation 1Phantoms, Imaging 1Paclitaxel 1Ipilimumab 1Immunoglobulin G 1Gemcitabine 1Fluid Therapy 1Disulfides 1Congresses as Topic 1Carboplatin 1CTLA-4 Antigen 1Brachytherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Carcinosarcoma × trastuzumab deruxtecan × Clear all
NCT04704661 2026-05-13

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

National Cancer Institute (NCI)

Phase 1 Active not recruiting
51 enrolled
BreastGastrointestinalGynecologicHead & NeckSarcoma

Breast Neoplasms, Carcinosarcoma, Colonic Neoplasms, Neoplasm Metastasis, Salivary Gland Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡